Image_1_PTEN Inhibition Protects Against Experimental Intracerebral Hemorrhage-Induced Brain Injury Through PTEN/E2F1/β-Catenin Pathway.jpeg
Intracerebral hemorrhage (ICH) is a subtype of stroke with highest mortality and morbidity. We have previously demonstrated that dipotassium bisperoxo (picolinato) oxovanadate (V), (bpV[pic]) inhibits phosphatase and tensin homolog (PTEN) and activates extracellular signal-regulated kinase (ERK)1/2. In this study, we examined the effect of bpV[pic] in the rat ICH model in vivo and the hemin-induced injury model in rat cortical cultures. The rat model of ICH was created by injecting autologous blood into the striatum, and bpV[pic] was intraperitoneally injected. The effects of bpV[pic] were evaluated by neurological tests, Fluoro-Jade C (FJC) staining, and Nissl staining. We demonstrate that bpV[pic] attenuates ICH-induced brain injury in vivo and hemin-induced neuron injury in vitro. The expression of E2F1 was increased, but β-catenin expression was decreased after ICH, and the altered expressions of E2F1 and β-catenin after ICH were blocked by bpV[pic] treatment. Our results further show that bpV[pic] increases β-catenin expression through downregulating E2F1 in cortical neurons and prevents hemin-induced neuronal damage through E2F1 downregulation and subsequent upregulation of β-catenin. By testing the effect of PTEN-siRNA, PTEN cDNA, or combined use of ERK1/2 inhibitor and bpV[pic] in cultured cortical neurons after hemin-induced injury, we provide evidence suggesting that PTEN inhibition by bpV[pic] confers neuroprotection through E2F1 and β-catenin pathway, but the neuroprotective role of ERK1/2 activation by bpV[pic] cannot be excluded.
History
References
- https://doi.org//10.1016/j.ajpath.2010.12.023
- https://doi.org//10.1038/nm.4309
- https://doi.org//10.1016/j.tins.2007.08.006
- https://doi.org//10.1186/s13041-016-0241-3
- https://doi.org//10.1172/jci81542
- https://doi.org//10.1097/MCC.0b013e328342f823
- https://doi.org//10.1074/jbc.275.16.11553
- https://doi.org//10.1016/j.ccr.2007.11.031
- https://doi.org//10.1007/s12975-009-0004-x
- https://doi.org//10.1083/jcb.201105009
- https://doi.org//10.1016/j.cellsig.2014.07.004
- https://doi.org//10.1016/j.neubiorev.2014.09.005
- https://doi.org//10.1111/jpi.12182
- https://doi.org//10.1007/s12975-016-0506-2
- https://doi.org//10.1038/ncomms14819
- https://doi.org//10.1161/strokeaha.111.000427
- https://doi.org//10.2147/dddt.s204956
- https://doi.org//10.1186/1742-2094-9-46
- https://doi.org//10.1161/strokeaha.110.579011
- https://doi.org//10.1007/s11064-018-2558-z
- https://doi.org//10.1161/strokeaha.117.017681
- https://doi.org//10.1097/01.wcb.0000084249.20114.fa
- https://doi.org//10.1097/00001756-199909090-00004
- https://doi.org//10.1007/s00109-012-0974-0
- https://doi.org//10.1074/jbc.273.22.13375
- https://doi.org//10.1080/15384101.2017.1388970
- https://doi.org//10.1097/00004647-200002000-00022
- https://doi.org//10.3389/fonc.2015.00024
- https://doi.org//10.1038/nature07310
- https://doi.org//10.1523/jneurosci.5449-03.2004
- https://doi.org//10.1073/pnas.170144197
- https://doi.org//10.1523/jneurosci.20-09-03104.2000
- https://doi.org//10.4161/23723548.2014.970480
- https://doi.org//10.1161/strokeaha.117.018904
- https://doi.org//10.1016/j.febslet.2004.03.102
- https://doi.org//10.1128/mcb.14.12.8166
- https://doi.org//10.1111/j.1471-4159.2009.06398.x
- https://doi.org//10.1038/cdd.2017.12
- https://doi.org//10.1016/j.nbd.2010.09.007
- https://doi.org//10.1021/nn405077y
- https://doi.org//10.1038/cdd.2014.165
- https://doi.org//10.1016/j.neuropharm.2017.03.025
- https://doi.org//10.1016/j.expneurol.2018.08.013
- https://doi.org//10.26355/eurrev_201906_18077
- https://doi.org//10.1016/j.febslet.2006.12.055
- https://doi.org//10.1111/bph.13727
- https://doi.org//10.1159/000445170
- https://doi.org//10.1242/jcs.095729
- https://doi.org//10.1177/0271678x16648712
CC BY 4.0